$IRME
IR-Med, Inc. Stock $irme

$irme Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045844 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$396.0K
YoY Change		-45.6%
% of Gross Profit
Research & Development		$205.0K
YoY Change		-56.29%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$601.0K
YoY Change		-49.79%
Operating Profit		-$601.0K
YoY Change		-49.79%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$3.000K
YoY Change		-83.33%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings		-$598.0K
YoY Change		-49.28%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share		-$0.01
COMMON SHARES
Basic Shares Outstanding	71.01M shares	70.74M shares
Diluted Shares Outstanding		70.76M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$392.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables		$51.00K
Other Receivables
Total Short-Term Assets		$443.0K
YoY Change		-72.43%
LONG-TERM ASSETS
Property, Plant & Equipment		$39.00K
YoY Change		-29.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$90.00K
YoY Change		-45.78%
TOTAL ASSETS
Total Short-Term Assets		$443.0K
Total Long-Term Assets		$90.00K
Total Assets		$533.0K
YoY Change		-69.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$68.00K
YoY Change		-83.29%
Accrued Expenses		$157.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities		$531.0K
YoY Change		-5.35%
SHAREHOLDERS EQUITY
Retained Earnings		-$16.46M
YoY Change		21.31%
Common Stock		$70.00K
YoY Change		1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$2.000K
YoY Change
Total Liabilities & Shareholders Equity		$533.0K
YoY Change		-69.94%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$598.0K
YoY Change		-49.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.16	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56492
	dei	Entity Registrant Name EntityRegistrantName	IR-Med, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ZHR Industrial Zone
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rosh Pina
	dei	Local Phone Number LocalPhoneNumber	4-655-5054
	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1197000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1617000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	365000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001839133
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-4516398
	dei	Entity Address Country EntityAddressCountry	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	1231400
	dei	City Area Code CityAreaCode	972
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1125000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	IRME	Research And Development Expense Government Grants ResearchAndDevelopmentExpenseGovernmentGrants		usd
	IRME	Research And Development Expense Government Grants ResearchAndDevelopmentExpenseGovernmentGrants		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2024Q3	IRME	Accounts Payable Lease Liability AccountsPayableLeaseLiability		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Trading Symbol TradingSymbol	IRME
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71008144	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	392000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	767000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	81000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	443000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	848000	usd
CY2024Q3	IRME	Long Term Restricted Deposit LongTermRestrictedDeposit	11000	usd
CY2023Q4	IRME	Long Term Restricted Deposit LongTermRestrictedDeposit	11000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	90000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	151000	usd
CY2024Q3	us-gaap	Assets Assets	533000	usd
CY2023Q4	us-gaap	Assets Assets	999000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	376000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	473000	usd
CY2024Q3	IRME	Stockholders Loans StockholdersLoans	155000	usd
CY2023Q4	IRME	Stockholders Loans StockholdersLoans	161000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	531000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	634000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70783144	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69931056	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	70000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	69000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16392000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15135000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16460000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14839000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	365000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	533000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	999000	usd
CY2024Q3	IRME	Research And Development Expenses Incurred ResearchAndDevelopmentExpensesIncurred	257000	usd
CY2023Q3	IRME	Research And Development Expenses Incurred ResearchAndDevelopmentExpensesIncurred	469000	usd
	IRME	Research And Development Expenses Incurred ResearchAndDevelopmentExpensesIncurred	881000	usd
	IRME	Research And Development Expenses Incurred ResearchAndDevelopmentExpensesIncurred	1570000	usd
CY2024Q3	IRME	Research And Development Expense Government Grants ResearchAndDevelopmentExpenseGovernmentGrants	-52000	usd
	IRME	Research And Development Expense Government Grants ResearchAndDevelopmentExpenseGovernmentGrants	-387000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	205000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	469000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	494000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1570000	usd
CY2024Q3	us-gaap	Marketing Expense MarketingExpense	29000	usd
CY2023Q3	us-gaap	Marketing Expense MarketingExpense	297000	usd
	us-gaap	Marketing Expense MarketingExpense	225000	usd
	us-gaap	Marketing Expense MarketingExpense	631000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	367000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	431000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	898000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1448000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-601000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3649000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-598000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1179000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1621000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70758796	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70758796	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68836598	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68836598	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70305346	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70305346	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69233573	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69233573	shares
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	755000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	503000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1621000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2592000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1000000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1258000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1212000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	363000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	40000	usd
CY2024Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	197000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-598000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2008000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2008000	usd
CY2023Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	383000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1179000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1212000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1212000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1621000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	503000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1258000	usd
	us-gaap	Depreciation Depreciation	17000	usd
	us-gaap	Depreciation Depreciation	17000	usd
	IRME	Increase Decrease In Accrued Financial Income Expenses IncreaseDecreaseInAccruedFinancialIncomeExpenses	-4000	usd
	IRME	Increase Decrease In Accrued Financial Income Expenses IncreaseDecreaseInAccruedFinancialIncomeExpenses	11000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-58000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-76000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1125000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2478000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	755000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1000000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	5000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	750000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-375000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1478000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	767000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3002000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	392000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1524000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zekojN6WDx5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ta_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_82E_znqZve0SqTne">General</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 71.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc. (OTC QB: IRME, hereinafter: the “Parent Company”) was incorporated in Nevada in 2007. IR-Med, Inc. was previously named International Display Advertising, Inc. and changed its name to IR-Med, Inc. in January 2021.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered office of IR-Med, Inc. and the corporate headquarters and research facility of IR. Med, Ltd. (the “Subsidiary”) are located in Rosh Pina, Israel. The Parent Company and the Subsidiary are at times collectively referred to as the “Company”.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 9, 2024, the Company’s first device, the P<i>ressureSafe</i>, decision support device received a U.S. Food and Drug Administration (FDA) listing certification. <i>PressureSafe</i> is classified as a Class I device. Following the listing certification of the <i>PressureSafe </i>device, the Company has started the preparations for the commercial launch of its first device, the <i>PressureSafe. </i>The Company is developing its technology through its Subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with an Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The initial product candidates which are currently in various stages of development are non-invasive, user friendly and designed to address the medical needs of large and growing target patient groups by offering earlier and more accurate information for detection, which is expected to reduce healthcare expenses and reduce the widespread reliance on antibiotics administration, and other interventional options optimizing the delivery of targeted medical services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern </b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is starting preparations for the commercial launch of its first device the “PressureSafe” and does not expect to generate significant revenue until such time as the Company shall have completed the design and development of its initial product candidates and initiate market activities for its first commercial product. During the nine months ended September 30, 2024, the Company has incurred losses of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20240101__20240930_zjRtr8njlZ13" title="Net loss">1,621</span> thousand and had a negative cash flow from operating activities of $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240930_zJ7vq2vPWhn" title="Net cash provided operating activities">1,125</span> thousand. The accumulated deficit as of September 30, 2024 is $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240930_zqipEiZtoRf4" title="Accumulated deficit">16,460</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the current expected level of operating expenditures, the Company’s cash resources as of September 30, 2024 shall not be sufficient for a period of at least 12 months from the issuance of these consolidated financial statements. Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, in the event financing is not obtained, the Company may pursue cost cutting measures or may be required to delay, reduce the scope of, or eliminate any of its development programs, these events could have a material adverse effect on its business. These factors raise significant doubt about the Company ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Iron Swords War </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further to the described in Note 1B to the Company’s Annual Report on for the year ended December 31, 2023, the Company did not experience significant changes in its activities from the continuation of the war during the reporting period. However, the Company’s management continues to believe that the general conditions have brought further difficulties in management’s efforts to seek additional financing arrangements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assesses, on the basis of the information it has as of the date of the approval of these financial statements, that the current events and the escalation in security in Israel, may have a material effect on its business plans in the short term and may cause delays in the Company’s research and development activities and in its marketing efforts. Since this is an event that is not under the control of the Company and matters such as the continuation of the multi front war in Israel may affect the Company’s assessments, as of the reporting date the Company is unable to assess the extent of the effect of the Iron Swords War on its business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Interim Unaudited Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Net Income Loss NetIncomeLoss	-1621000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16460000	usd
CY2024Q1	IRME	Patient Budget PatientBudget	3761978000
CY2024Q1	IRME	Patient Budget PatientBudget	1030000000	usd
CY2024Q1	IRME	Grant Total Budget Disbursed Installment GrantTotalBudgetDisbursedInstallment	0.50	pure
CY2024Q2	IRME	Aggregate Gross Proceeds AggregateGrossProceeds	715000000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	64000	shares
CY2024Q2	IRME	Officers Compensation Of Car Expenses OfficersCompensationOfCarExpenses	5000000
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	35000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	62000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	157000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	160000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	66000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	98000	usd
CY2024Q3	IRME	Accounts Payable Advance From Customers AccountsPayableAdvanceFromCustomers	50000	usd
CY2023Q4	IRME	Accounts Payable Advance From Customers AccountsPayableAdvanceFromCustomers	50000	usd
CY2023Q4	IRME	Accounts Payable Lease Liability AccountsPayableLeaseLiability	39000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	68000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	64000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	376000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	473000	usd
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	13139791	shares
CY2024Q3	us-gaap	Share Price SharePrice	0.41
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.42
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15544175	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1831500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1715500	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.43
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15428175	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	97088	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	503000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1258000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	197000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	383000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	503000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1258000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.84	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.16	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9537	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0439	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0416	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.64
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.88
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2023Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	2100000	usd

Files In Submission

Name	View Source	Status
0001493152-24-045844-index-headers.html	Edgar Link	pending
0001493152-24-045844-index.html	Edgar Link	pending
0001493152-24-045844.txt	Edgar Link	pending
0001493152-24-045844-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
irme-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
irme-20240930_cal.xml	Edgar Link	unprocessable
irme-20240930_def.xml	Edgar Link	unprocessable
irme-20240930_lab.xml	Edgar Link	unprocessable
irme-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRME
IR-Med, Inc. Stock $irme

2024 Q4 Form 10-Q Financial Statement

#000149315224045844 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRME IR-Med, Inc. Stock $irme

2024 Q4 Form 10-Q Financial Statement

#000149315224045844 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRME
IR-Med, Inc. Stock $irme